Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
暂无分享,去创建一个
G. Remuzzi | C. Bedrosian | N. Sheerin | A. Trivelli | C. Licht | L. Greenbaum | C. Legendre | R. Furman | D. Cohen | C. Loirat | P. Muus | K. Douglas | T. Goodship | Y. Delmas | M. Herthelius | M. Hourmant | O. Gaber | S. Babu | Yahsou Delmas
[1] J. Shatzel,et al. Syndromes of Thrombotic Microangiopathy. , 2017, The Medical clinics of North America.
[2] R. Torra,et al. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento: Documento de consenso , 2015 .
[3] G. Ardissino,et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] J. Pu,et al. Successful discontinuation of eculizumab therapy in a patient with aHUS , 2014, Annals of Hematology.
[5] V. D’Agati,et al. Phenotypic expansion of DGKE-associated diseases. , 2014, Journal of the American Society of Nephrology : JASN.
[6] A. Jankauskienė,et al. Macrovascular involvement in a child with atypical hemolytic uremic syndrome , 2014, Pediatric Nephrology.
[7] Ikuyo Yamaguchi,et al. Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease , 2014, Pediatric Nephrology.
[8] G. Keating. Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome , 2013, Drugs.
[9] G. Remuzzi,et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.
[10] S. Cataland,et al. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation , 2013, Annals of Hematology.
[11] P. Chowdhury,et al. The use of eculizumab in renal transplantation , 2013, Clinical transplantation.
[12] L. Rostaing,et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[13] John Hwa,et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome , 2013, Nature Genetics.
[14] N. Kamar,et al. Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[15] E. Baskın,et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab , 2013, Pediatric Nephrology.
[16] G. Ardissino,et al. Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] V. Frémeaux-Bacchi,et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.
[18] B. Acar,et al. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation , 2012, Pediatric Nephrology.
[19] R. Montgomery,et al. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft , 2012, Transplant international : official journal of the European Society for Organ Transplantation.
[20] P. Theofilou. Quality of Life in Patients Undergoing Hemodialysis or Peritoneal Dialysis Treatment , 2011, Journal of clinical medicine research.
[21] G. Remuzzi,et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[22] A. Garnier,et al. Plasmatherapy in atypical hemolytic uremic syndrome. , 2010, Seminars in thrombosis and hemostasis.
[23] P. Zipfel,et al. Thrombotic microangiopathies: new insights and new challenges , 2010, Current opinion in nephrology and hypertension.
[24] K. Amann,et al. Thrombotic microangiopathy: new insights , 2010, Current opinion in nephrology and hypertension.
[25] D. Geary,et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. , 2009, Blood.
[26] B. Hurault de Ligny,et al. Safety and Long‐Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic–Uremic Syndrome , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] D. Lambrechts,et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.
[28] G. Ariceta,et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome , 2009, Pediatric Nephrology.
[29] G. Remuzzi,et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. , 2009, The American journal of pathology.
[30] M. Neary,et al. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.
[31] R. Brodsky,et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.
[32] Tom Greene,et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.
[33] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[34] G. Remuzzi,et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.
[35] Yoshihiro Kokubo,et al. FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.
[36] R. Browne,et al. Validation of the Center for Medicare and Medicaid Services algorithm for eligibility for dialysis , 2004, Pediatric Nephrology.
[37] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] S. D. Subba Rao,et al. Atypical hemolytic uremic syndrome. , 2002, Indian pediatrics.
[39] R. Rabin,et al. EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.
[40] L. Matis,et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. , 1995, The Journal of clinical investigation.
[41] S. Rodríguez de Córdoba,et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. , 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[42] Richard J. H. Smith,et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. , 2014, Journal of the American Society of Nephrology : JASN.
[43] D. Solís. US Food and Drug Administration , 2010 .
[44] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.